Gabapentin Tablets(Er) Suppliers & Bulk Manufacturers
Available Forms: Tablet(ER)
Available Strengths: 600 mg, 800 mg, 300 mg (ER)
Reference Brands: US: Neurontin®, Gralise®, Horizant® (ER); EU: Neurontin®, Gabantin®
Category:
Antipsychotropic Drugs
Gabapentin ER tablets modulate calcium channels by binding to the alpha-2-delta subunit, reducing excitatory neurotransmitter release. They are primarily used to treat postherpetic neuralgia in adults. The extended-release formulation ensures sustained pain relief and improved patient compliance with once-daily dosing, minimizing peak-related side effects.
Gabapentin Tablets(ER) is available in Tablet(ER)
and strengths such as 600 mg, 800 mg, 300 mg (ER).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Gabapentin Tablets(ER) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Gabapentin Tablets(ER) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Gabapentin Extended-Release (ER) tablets are FDA-approved in the USA for the management of postherpetic neuralgia in adults. Marketed under brand names like Gralise, ER formulations are not interchangeable with immediate-release versions. They must be taken with food and are subject to renal dose adjustments. In the European Union, Gabapentin ER tablets are not widely marketed; instead, immediate-release formulations dominate. Regulatory guidelines emphasize CNS side effects, withdrawal risks, and potential misuse. It is a prescription-only medicine across the EU and US. Explore more forms and global sources of Gabapentin at Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing